Murmansk

Running trials

• Recruiting

  Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

  NCT07052578· Source

• Recruiting

  An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

  NCT07041606· Source

• Active, not recruiting

  Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

  NCT06521229· Source

• Recruiting

  Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

  NCT06472310· Source

• Active, not recruiting

  A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

  NCT05456867· Source

• Active, not recruiting

  A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

  NCT04035486· Phase 3· Source

• Active, not recruiting

  A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

  NCT03706690· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  NCT03298451· Phase 3· Source

• Active, not recruiting

  Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

  NCT03212404· Phase 1· Source

• Active, not recruiting

  Savolitinib vs. Sunitinib in MET-driven PRCC.

  NCT03091192· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• Endometrial cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia

  NCT06759519· Source